Biggest News Aggregation in the World
📰 Advanced Solid Tumors News

Page 9 - Advanced Solid Tumors News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Advanced Solid Tumors. Real-time updates on events, politics, business and more.

Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021

Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021 Gilead Sciences, Inc. and Kite, a Gilead Company, today announced that 16 abstracts representing the breadth of the Gilead-Kite Oncology portfolio will be presented at the American Society of Clinical Oncology Annual Meeting from June 4-8, 2021. The abstracts, including two oral presentations, expand on the clinical profiles of Gilead’s antibody-drug conjugate as well as Kite’s chimeric antigen recept...
United States Santa Monica Foster City Jacquie Ross Merdad Parsey Sacituzumab Govitecan

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021 LUMAKRAS™ (Sotorasib)¹ Overall Survival and Biomarker Subgroup Analyses From Registrational Phase 2 CodeBreaK 100 Trial in KRAS G12C-Mutated Non-Small Cell Lung Cancer New Data From the Phase 2 FIGHT Trial with Bemarituzumab in Advanced Gastric and Gastroesophageal Junction Cancers News provided by Share this article Share this article THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that ...
United States Puerto Rico Megan Fox Stevens Johnson Fluorouracil Leucovorin Talimogene Laherparepvec

Salarius Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentations at the 2021 American Society of Clinical Oncology Annual Meeting

Message : Required fields HOUSTON, April 19, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that all three submitted abstracts detailing research involving seclidemstat were accepted for poster presentations, with one abstract also selected for a poster discussion session, at the 2021 American Society of Cl...
United States David Arthur Johanna Bennett Maureen Mcenroe Miriam Miller Tiberend Strategic Advisors Inc

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with ... Helsinn Healthcare S.A.January 12, 2021 GMT Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and ra...
Paola Bonvicini Riccardo Braglia Helsinn Investment Fund Helsinn Group Vice Taiho Pharmaceutical Co Ltd Swiss Pharma Company
Source: apnews.com

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities January 12, 2021 03:30 ET | Source: Helsinn Healthcare S.A. Helsinn Healthcare S.A. Lugano/Pazzallo, SWITZERLAND Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss ph...
Paola Bonvicini Johns Hopkins Riccardo Braglia Helsinn Investment Fund Helsinn Group Vice Taiho Pharmaceutical Co Ltd

Helsinn Healthcare S.A.: Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

(1) Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, January 12, 2021 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities. TAS0953/HM06 is an investigational oral treatment which ...
Kostenloser Wertpapierhandel Paola Bonvicini Johns Hopkins Riccardo Braglia Helsinn Investment Fund Helsinn Group Vice

Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering

Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021 Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 non-responders into responders, the Company will provide the next update on its immuno-oncology phase I basket study eval...
United States United Kingdom France General Ricky Bhajun Brandon Owens Porter Novelli

Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma

Published: Dec 23, 2020 SAN MATEO, Calif., Dec. 23, 2020 /PRNewswire/ -- Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors (ClinicalTrials.gov Identifier: NCT04305795) has enrolled and treated its first patient in the United States, at The University of Texas MD Anderson Cancer Center, Houston, Texas. Approximately 7...
United States Hisataka Kobayashi Hiroshi Mikitani Japanese Ministry Of Health National Cancer Institute University Of Texas Md Anderson Cancer Center

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science